Microvascular Therapeutics Finalizes Facility Certification for the Production of Its Product, MVT-100

Microvascular Therapeutics (MVT), a clinical stage biotechnology company, finalized its manufacturing facility certifications for the GMP production of its first product, MVT-100. - April 21, 2022

Microvascular Therapeutics Receives Funds from Commercialization Readiness Program for the Development of Its Ultrasound Contrast Agent, MVT-100

MicrovMicrovascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Commercialization Readiness Program grant from the National Institute of Heart, Lung, and Blood Institute (NHLBI). Wyatt Unger, MD, MBA, Chief Medical Officer of MVT said, “We are... - April 09, 2022

Timothy Healey Joins the Board of Director at Microvascular Therapeutics

Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Timothy Healey to the MVT Board of Directors. Mr. Healey bring a global perspective to pharmaceutical launch and commercialization. “I am very pleased and honored... - February 23, 2022

ImaRx Investments Receives ISO-7 Certification for Its GMP Manufacturing Suite: Both Microvascular Therapeutics and NuvOx Pharma Will Benefit

ImaRx Investments, LLC, an investment firm based in Tucson, Arizona, has received ISO-7 certification on February 1st for its GMP manufacturing suite. The 1,800 square foot, ISO-5 capable clean room is designed for manufacturing injectable drugs. The facility is the only one of its kind in Southern... - February 08, 2022

Shiv Kapoor Joins the Board of Directors at Microvascular Therapeutics

Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Shiv Kapoor to the MVT Board of Directors. Mr. Kapoor will bring extensive experience in corporate strategy and financing from both biotechnology and finance... - February 03, 2022

Microvascular Therapeutics Has Received Funds from the National Heart, Lung and Blood Institute (NHLBI)

Microvascular Therapeutics (MVT) has received funds from the from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health for its program to treat cardiovascular disease, which kills more Americans than any other disease. As a leader in fluorocarbon... - July 19, 2021

Microvascular Therapeutics Receives NIH SBIR Phase I Funds for Its Alzheimer Program

Microvascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Institute of Aging (NIA), part of the National Institutes of Health (NIH). Wyatt Unger, MD, MBA, President and CEO of MVT said,... - August 03, 2020

Microvascular Therapeutics Receives NIH SBIR Phase I Funds for Its Program to Treat Heart Attack

Microvascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health. Wyatt Unger, MD, MBA, President and CEO of... - July 31, 2020

Press Releases 1 - 8 of 8